Published • loading... • Updated
US House committee opens investigation into Merck, AbbVie China drug trials
Lawmakers seek details on data protection and informed consent after citing more than 100 AbbVie studies in China and 224 Merck studies since 2005.
- On Monday, the China Select Committee opened national security investigations into drugmakers Merck and AbbVie regarding their clinical trial sites in China, seeking details by July 17.
- Lawmakers cite concerns that research at PRC military hospitals exposes American companies to security risks, potentially transferring intellectual property to the Chinese military.
- New Jersey-based Merck has collaborated on 224 studies in China, including at least 31 trials in Xinjiang and 40 at military-affiliated centers.
- Merck asserted that patient safety and ethical integrity remain priorities, while a Chinese embassy spokesperson called the committee's actions "nothing credible."
- By 2024, the U.S. share of early drug development programs fell to around 37% from 48% in 2015, while China's share rose to over 32% from 8%.
Insights by Ground AI
13 Articles
13 Articles
Lawmakers press Eli Lilly for China drug trials tied to military-linked hospitals
Eli Lilly faces a congressional investigation into its China clinical trials at People's Liberation Army hospitals and Xinjiang facilities amid biotechnology competition concerns.
·New York, United States
Read Full Article
House Committee Opens Investigation Into Merck, AbbVie China Drug Trials
·Washington, United States
Read Full Article
A bipartisan group of US legislators opened national security investigations to determine whether five pharmacists, including Merck and AbbVie, were involved in clinical trials conducted in China that would have helped boost the communist country's military capacity.
·Brazil
Read Full Article
4th of July SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources13
Leaning Left1Leaning Right7Center4Last UpdatedBias Distribution59% Right
Bias Distribution
- 59% of the sources lean Right
59% Right
C 33%
R 59%
Factuality
To view factuality data please Upgrade to Premium
